Main Article Content
Abstract
Leukemia Limfoblastik Akut (LLA) adalah penyakit keganasan yang diakibatkan oleh adanya mutasi somatik yang multistep pada sel progenitor limfoid. Meskipun cukup jarang terjadi pada orang dewasa, namun risiko meningkat seiring usia. Sebanyak 20% kasus dari LLA adalah dewasa. Sebagian kasus muncul pada anak, namun kematian terjadi lebih banyak pada dewasa. Prognosis LLA pada dewasa tergantung dari subtipe nya dan dapat memburuk dengan cepat tanpa tatalaksana yang tepat. Dibutuhkan update pengetahuan baru tentang tatalaksana LLA yang relaps ataupun refrakter. Pada tahun 2017, US Food and Drug Administration menyetujui Inotuzumab Ozogamicin sebagai terapi baru untuk kasus LLA relaps atau refrakter pada dewasa.
Article Details
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
References
- Kaushansky K, Lictman M, Prchal J, Levi M, Press O, Burns L,et al. Williams Hematology.9th Edition. United States. McGrawHill. 2016.
- Sudoyo A W, Setyohadi B, Alwi I dkk. Buku Ajar Ilmu Penyakit Dalam. Edisi V.Jakarta. 2009.
- Fauci AS, Kasper DL, Longo DL, Braunwald E, Hauser SL, Lameson JL, et al, editors. Harrison’s Principles of Internal Medicine. 17th ed. New York: McGraw-Hill. 2008.
- Keohane E, Smith L, Walenga J. Rodak’s Hematology.5th Edition. Elsevier. 2016.
- Arber D, George T, Sojitra P. ASH-CAP Guidelines for the Diagnosis of Acute Leukemia. American Society of Hematology. 2017.
- Food and Drug Administration. FDA Approves New Treatment for Adults with Relapsed or Refractory Acute Lymphoblastic Leukemia. US Department of Health and Human Services. 2017.
- Uy N, Nadeaue M, Stahl M, Zeidan AM. Inotuzumab Ozogamicin in the Treatment of Relapsed/Refractory Acute B cell Lymphoblastic Leukemia. USA: Journal of Blood Medicine. 2017.
- Simon S. FDA Approves Besponsa (Inotuzumab Ozogamicin) for Acute Lymphoblastic Leukemia in Adults. American Cancer Society. 2017.
- Fala L. Besponsa (Inotuzumab Ozogamicin) Approved for Adults with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia. American Health and Drug Benefits.2018.
- Elias J, Anjali S, Matthias S, Wendy S, Michaela L, Nocola G, et al. Efficacy and Safety of Inotuzumab Ozogamicin in Older Patients with Relaps/Refractory Acute Lymphoblastic Leukemia Enrolled in the Global Phase 3 Randomized Controlled INO-VATE Trial. Netherlands : European Hematology Association. 2016.
- DeAngelo D, Stock W, Petersdorf S, Wang SL, Volkert A, Vandendries E, et al. Weekly Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymhoblastic Leukemia. American Society of Hematology. 2012.
- Toich L. Besponsa Approved for Acute Lymphoblastic Leukemia. The American Journal of Pharmacy Benefits. 2017.
References
Kaushansky K, Lictman M, Prchal J, Levi M, Press O, Burns L,et al. Williams Hematology.9th Edition. United States. McGrawHill. 2016.
Sudoyo A W, Setyohadi B, Alwi I dkk. Buku Ajar Ilmu Penyakit Dalam. Edisi V.Jakarta. 2009.
Fauci AS, Kasper DL, Longo DL, Braunwald E, Hauser SL, Lameson JL, et al, editors. Harrison’s Principles of Internal Medicine. 17th ed. New York: McGraw-Hill. 2008.
Keohane E, Smith L, Walenga J. Rodak’s Hematology.5th Edition. Elsevier. 2016.
Arber D, George T, Sojitra P. ASH-CAP Guidelines for the Diagnosis of Acute Leukemia. American Society of Hematology. 2017.
Food and Drug Administration. FDA Approves New Treatment for Adults with Relapsed or Refractory Acute Lymphoblastic Leukemia. US Department of Health and Human Services. 2017.
Uy N, Nadeaue M, Stahl M, Zeidan AM. Inotuzumab Ozogamicin in the Treatment of Relapsed/Refractory Acute B cell Lymphoblastic Leukemia. USA: Journal of Blood Medicine. 2017.
Simon S. FDA Approves Besponsa (Inotuzumab Ozogamicin) for Acute Lymphoblastic Leukemia in Adults. American Cancer Society. 2017.
Fala L. Besponsa (Inotuzumab Ozogamicin) Approved for Adults with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia. American Health and Drug Benefits.2018.
Elias J, Anjali S, Matthias S, Wendy S, Michaela L, Nocola G, et al. Efficacy and Safety of Inotuzumab Ozogamicin in Older Patients with Relaps/Refractory Acute Lymphoblastic Leukemia Enrolled in the Global Phase 3 Randomized Controlled INO-VATE Trial. Netherlands : European Hematology Association. 2016.
DeAngelo D, Stock W, Petersdorf S, Wang SL, Volkert A, Vandendries E, et al. Weekly Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymhoblastic Leukemia. American Society of Hematology. 2012.
Toich L. Besponsa Approved for Acute Lymphoblastic Leukemia. The American Journal of Pharmacy Benefits. 2017.